Sti-571 in Chronic Myelogenous Leukaemia
Authors:
Open Access
- 2 October 2002
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 119 (1) , 15-24
Abstract
No abstract availableThis publication has 56 references indexed in Scilit:
- Imatinib Mesylate — A New Oral Targeted TherapyNew England Journal of Medicine, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Roots of Clinical Resistance to STI-571 Cancer TherapyScience, 2001
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeNew England Journal of Medicine, 2001
- Adaptive AmplificationCell, 2000
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- The Molecular Genetics of Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 1988
- Hematologic Remission and Cytogenetic Improvement Induced by Recombinant Human Interferon AlphaAin Chronic Myelogenous LeukemiaNew England Journal of Medicine, 1986